Arthneeti

Nidan Laboratories & Healthcare Q2 FY27 Share Price & Earnings Call Analysis

₹13.35-0.37% today
Market cap
₹19 Cr
P/E
15.34
ROE
2.58%
PEG
-0.81
Price to sales
0.76
Debt to equity
0.17
52W high / low
₹22.8 / ₹12.3
Sales growth (5Y)
4.62%
EBITDA margin
17.47%
Net profit margin
6.97%
Promoter holding
57.04%
Sales (last year)
₹24 Cr

Incorporated in 2000, Nidan Laboratories & Healthcare Ltd is in the business of providing various Healthcare and Diagnostics Services[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Services
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Aster DM QualityGood growth
    3
See all potential multibaggersWhere does Nidan Laboratories & Healthcare rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Services companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹867 Cr—
240%+Flat₹574 Cr21.8
3Aster DM Quality20–40%Up 2%+₹65,342 Cr124.7
420–40%Up 2%+₹14,999 Cr35.2
520–40%Up 2%+₹1,579 Cr15.6
620–40%Up 2%+₹587 Cr19.7

Sign up free to see every company in the sector ranking and track Nidan Laboratories & Healthcare.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services ranking

Financials of Nidan Laboratories & Healthcare

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Nidan Laboratories & Healthcare

Shareholding breakup across reporting periods.

Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +71.22%71.22%71.22%62.79%57.04%57.04%57.04%57.04%57.04%57.04%57.04%57.04%
Public +28.79%28.78%28.78%37.21%42.96%42.96%42.96%42.96%42.96%42.96%42.96%42.96%
No. of Shareholders2,7912,5162,4402,7772,8442,7902,5812,4892,4372,3622,3592,323

Financials of Nidan Laboratories & Healthcare

Quarterly Results

Quarter-by-quarter operating performance

No quarterly results data available for this company yet.

Financials of Nidan Laboratories & Healthcare

Profit & Loss

Annual income statement trend

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +20.0721.4120.3829.6624.2724.1824.5325.5424.44
Sales growth+6.68%-4.81%+45.53%-18.17%-0.37%+1.45%+4.12%-9.85%
Expenses +12.2313.7811.4920.2517.4717.7419.4720.7020.17
Operating Profit7.847.638.899.416.806.445.064.844.27
OPM %39.06%35.64%43.62%31.73%28.02%26.63%20.63%18.95%17.47%
Other Income +0.370.011.060.403.33-3.762.251.461.76
Interest4.753.743.462.662.222.182.141.962.09
Depreciation3.243.193.182.633.102.872.411.901.93
Profit before tax0.220.713.314.524.81-2.372.762.442.01
Tax %0.00%0.00%30.21%41.15%26.40%36.29%28.26%38.11%
Net Profit +0.220.712.302.663.54-3.231.981.511.16
EPS in Rs0.220.722.321.912.55-2.321.421.090.83
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials of Nidan Laboratories & Healthcare

Balance Sheet

Capital structure and asset base

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital9.909.909.9013.9013.9013.9013.9013.9013.90
Reserves0.411.133.4352.0055.5452.3154.2855.7956.88
Borrowings +32.1634.3538.0419.2910.9312.4411.1111.1712.25
Other Liabilities +0.58-0.172.373.294.033.903.653.143.28
Total Liabilities43.0545.2153.7488.4884.4082.5582.9484.0086.31
Fixed Assets +23.2820.1019.9220.4621.3917.9516.3314.9114.46
CWIP0.000.000.233.810.000.040.150.150.15
Investments0.530.530.270.000.000.0020.0020.0020.00
Other Assets +19.2424.5833.3264.2163.0164.5646.4648.9451.70
Total Assets43.0545.2153.7488.4884.4082.5582.9484.0086.31

Financials of Nidan Laboratories & Healthcare

Cash Flows

Operating, investing and financing cash movement

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +8.954.624.357.8310.975.522.361.67
Cash from Investing Activity +1.00-0.01-3.22-35.74-0.29-10.60-0.210.06
Cash from Financing Activity +-5.81-1.56-1.2228.72-10.37-0.49-3.10-1.63
Net Cash Flow4.143.05-0.100.800.32-5.57-0.950.10
Free Cash Flow9.954.611.131.3611.024.881.491.19
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit114%61%49%96%162%129%78%55%

Financials of Nidan Laboratories & Healthcare

Ratios

Working capital efficiency and return ratios

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days102.0392.5797.2565.9690.697.8518.9031.73
Inventory Days16.9812.8818.1725.99
Days Payable116.72-25.76213.05135.84
Cash Conversion Cycle2.29131.22-97.64-43.8990.697.8518.9031.73
Working Capital Days256.25291.69-189.3154.5243.46243.18-13.3933.58
ROCE %10.13%13.99%10.09%8.17%7.95%6.17%5.99%

Continue your research

What Nidan Laboratories & Healthcare's management said in earlier quarters

Others in Healthcare Services this season

  • Suven Life Sciences (Q2 FY27)

    91.92 lakhs for the quarter ended September 30, 2025, indicating a revenue increase of approximately 30.3%. Key results statement takeaways from Suven Life Scie

  • Aster DM Quality (Q2 FY27)

    Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10). Key investor presentation takeaways from Aster DM Quality Care Ltd's Q2

  • Fortis Healthcare (Q2 FY27)

    Q2FY27 consolidated revenue: INR 2,735 Cr, up 17.3% YoY (Q2FY26: INR 2,331 Cr) [Pages 11, 33] . Key investor presentation takeaways from Fortis Healthcare Ltd's

  • Dr Agarwal's Hea (Q2 FY27)

    Q2 FY27 revenue from operations: ₹655 Cr, up 31.4% YoY from ₹499 Cr in Q2 FY26 (Page 24) . Key investor presentation takeaways from Dr Agarwals Health Care Ltd'

Compare:vs Apollo Hospitalsvs Max Healthcarevs Manipal Health